Cefepime-Tazobactam Drug Review and Efficacy
Cefepime-tazobactam (WCK 4282) is a highly effective carbapenem-sparing agent that demonstrates superior activity against ESBL-producing Enterobacterales and comparable or superior activity to carbapenems against multidrug-resistant Gram-negative pathogens, with the notable exception of metallo-β-lactamase producers.
Mechanism and Spectrum of Activity
Cefepime-tazobactam combines a fourth-generation cephalosporin (cefepime 2g) with a β-lactamase inhibitor (tazobactam 2g) at high doses. This combination exploits cefepime's inherent stability against AmpC β-lactamases while tazobactam inhibits Class A extended-spectrum β-lactamases (ESBLs) and serine carbapenemases 1, 2.
Microbiological Efficacy
Against Enterobacterales:
- 97.6% of Enterobacterales isolates inhibited at ≤8 mg/L, comparable to meropenem (97.0%) and superior to piperacillin-tazobactam (88.0%) 1
- 95-100% coverage of organisms with penicillinases, AmpC, ESBLs, K1, or OXA-48 β-lactamases at 8+4 mg/L 3
- >90% activity against OXA-48 and KPC carbapenemase producers at 8+8 mg/L, though KPC-producing ST258 K. pneumoniae show higher MICs 2
- Metallo-β-lactamase producers (NDM, VIM) remain largely resistant, with only 80% of VIM producers susceptible 3
Against Pseudomonas aeruginosa:
- 82.7% inhibited at ≤8 mg/L and 92.2% at ≤16 mg/L, comparable to ceftolozane-tazobactam (93.5%) and superior to meropenem (76.0%) or piperacillin-tazobactam (76.4%) 1
- Less active than ceftolozane-tazobactam against AmpC-derepressed or high-efflux P. aeruginosa strains 2
Dosing Recommendations
Standard Dosing (Normal Renal Function)
Cefepime 2g + tazobactam 2g every 8 hours, infused over 90 minutes (1.5 hours) 4, 1
This regimen achieves:
- 99% probability of target attainment (PTA) against pathogens with MIC ≤16 mg/L 4
- Adequate coverage for ESBL-producing organisms resistant to both cefepime and piperacillin-tazobactam
Renal Dose Adjustments
Critical dosing modifications based on creatinine clearance (CrCL):
| CrCL (mL/min) | Dose | Frequency |
|---|---|---|
| ≥60 | 2g + 2g | Every 8 hours |
| 30-59 | 1g + 1g | Every 8 hours |
| 15-29 | 500mg + 500mg | Every 8 hours |
| 8-14 or hemodialysis | 500mg + 500mg | Every 12 hours |
For augmented renal clearance (CrCL 120-180 mL/min): Use standard 2g+2g dose but extend infusion to 4 hours to maintain adequate exposure 4
Critical Caveat on Cefepime Dosing
Standard cefepime dosing from FDA labeling 5 differs significantly from the high-dose cefepime-tazobactam combination. The combination specifically requires 2g cefepime + 2g tazobactam to achieve carbapenem-like activity, not the standard cefepime doses of 0.5-1g used for routine infections.
Safety Profile and Neurotoxicity Risk
Neurotoxicity: The Primary Safety Concern
Cefepime has the second-highest pro-convulsive activity among β-lactams (relative activity 160 vs. penicillin G = 100), exceeded only by cefazolin (294) 6.
Critical neurotoxicity thresholds:
- Trough concentrations >22 mg/L (intermittent infusion) or steady-state >35 mg/L (continuous infusion) associated with 50% risk of neurotoxicity 6
- Manifestations include encephalopathy, confusion, hallucinations, myoclonus, seizures, and status epilepticus—sometimes fatal 6
High-Risk Populations
Renal impairment is the dominant risk factor:
- 48% of neurotoxicity cases occur in overexposed patients
- 26% occur even with appropriate renal dose adjustment 6
- Elderly patients are particularly vulnerable due to age-related renal decline 5
Therapeutic drug monitoring (TDM) should be strongly considered in patients with:
- Any degree of renal impairment
- Unexplained neurological symptoms during treatment
- Elderly patients (≥65 years)
- ICU patients receiving high-dose therapy 6
Other Safety Considerations
- Pregnancy: Limited data suggest no definitive risk; cephalosporins have not been associated with major birth defects in available studies 5
- Lactation: Cefepime present in breast milk at low concentrations (0.5 mcg/mL); minimal infant exposure expected 5
- Pediatric use: Safety established for ages ≥2 months; insufficient data for younger infants 5
Clinical Applications
Primary Indications
Cefepime-tazobactam serves as a carbapenem-sparing agent for:
- Complicated urinary tract infections and pyelonephritis caused by ESBL-producing Enterobacterales
- Hospital-acquired and ventilator-associated pneumonia due to resistant Gram-negatives
- Complicated intra-abdominal infections (requires metronidazole for anaerobic coverage) 5
- Febrile neutropenia with suspected resistant pathogens
- Complicated skin and soft tissue infections caused by resistant organisms
When NOT to Use
Absolute contraindications based on resistance patterns:
- Metallo-β-lactamase producers (NDM, most VIM) - use aztreonam + ceftazidime-avibactam combination instead 7
- Carbapenem-resistant Acinetobacter baumannii (CRAB) - guidelines conditionally recommend against cefiderocol; use polymyxins or sulbactam combinations 7
- Suspected or confirmed meningitis - inadequate CNS penetration; use alternative agents 5
Guideline-Based Treatment Approach
For carbapenem-resistant Enterobacterales (CRE) with serine carbapenemases (KPC, OXA-48):
- Severe infections: Cefepime-tazobactam represents a viable alternative when newer β-lactam/β-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam) are unavailable 7
- Monotherapy is appropriate for susceptible isolates in severe infections 7
For difficult-to-treat Pseudomonas aeruginosa:
- Cefepime-tazobactam provides broader coverage than piperacillin-tazobactam but may be less active than ceftolozane-tazobactam against specific resistance mechanisms 1, 2
In Vivo Efficacy Data
Animal model studies demonstrate:
- >1 log₁₀ CFU reduction against all ESBL/AmpC-producing Enterobacterales and P. aeruginosa 8
- Variable activity against OXA-48-like producers
- Bacteriostasis against KPC producers at low inoculum, but only growth suppression at standard inoculum 8
This supports clinical use against ESBL producers but suggests caution with KPC-producing organisms at high bacterial burdens.
Practical Implementation
Infusion strategy is critical: The 90-minute (1.5-hour) infusion optimizes pharmacodynamic target attainment. Shorter infusions may compromise efficacy 4, 1.
Monitor for neurotoxicity vigilantly: Any unexplained neurological change warrants immediate consideration of cefepime toxicity, temporary drug suspension, and TDM if available 6.
Renal function assessment is mandatory: Calculate CrCL using Cockcroft-Gault equation and adjust doses accordingly. Re-assess renal function if clinical status changes 5, 4.
Combination therapy considerations: Unlike older agents, monotherapy with cefepime-tazobactam is appropriate for susceptible organisms in severe infections, avoiding unnecessary combination toxicity 7.